BASKING RIDGE, N.J. (August 30, 2018) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular indications,  announces today that David J. Mazzo, PhD, President and Chief Executive Officer of Caladrius Biosciences, will present a corporate overview at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., on Wednesday, September 5 at 11:15 a.m. Eastern time….

Caladrius Biosciences Reports 2018 Second Quarter and First Six Months Financial Results Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J. (August 9, 2018) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular indications, announces financial results for the three and six months ended June 30, 2018 and provides a business update. Highlights of the 2018 second quarter…

Caladrius Biosciences to Host Second Quarter 2018 Financial Results Conference Call on Thursday, August 9, 2018 at 4:30 p.m. ET BASKING RIDGE, N.J. (August 2, 2018) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company with multiple technology platforms targeting select cardiovascular indications and autoimmune diseases, announces that the Company will release financial results for the three and six months ended June 30, 2018 after close of the U.S. financial markets…

BASKING RIDGE, N.J. (June 19, 2018) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company with multiple technology platforms targeting select cardiovascular indications and autoimmune diseases, announces today that the U.S. Food and Drug Administration (“FDA”) has granted regenerative medicine advanced therapy (“RMAT”) designation to the Company’s late-stage CD34+ cell therapy program for the treatment of refractory angina. The FDA grants the RMAT designation to regenerative medicine therapies intended to treat a…

Caladrius Biosciences Sells Rights to Counter-Flow Centrifugation System to Hitachi Chemical Advanced Therapeutics Solutions Sale of non-core asset brings $2.5 million in non-dilutive funding BASKING RIDGE, N.J. (June 5, 2018) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular indications, announces today that the Company has sold for $2.5 million its ownership interest in a development-stage, fully enclosed, automated, programmable counter-flow centrifugation…

Caladrius Biosciences Reports 2018 First Quarter Financial Results Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J. (May 10, 2018) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular indications, announces financial results for the three months ended March 31, 2018 and provides a business update. Highlights of the 2018 first quarter and recent weeks include: Reported results…

Caladrius Biosciences to Host First Quarter 2018 Financial Results Conference Call on Thursday, May 10, 2018 at 4:30 p.m. Eastern Time BASKING RIDGE, N.J. (May 3, 2018) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology indications, announces that the Company will release financial results for the three months ended March 31, 2018 after close of the U.S. financial markets on Thursday,…

“We are very pleased to receive SAKIGAKE status for CLBS12 in Japan. As a designated medicine under the SAKIGAKE Designation system, CLBS12 will have prioritized consultation, a dedicated review system to support the development and review process, as well as reduced review time from the normal 12 to 6 months. This is great news not only in practical terms, but also because we believe that it reflects the recognition by MHLW and PMDA of the therapeutic potential of CLBS12 for the patient population in desperate need of therapeutic options,” Douglas W. Losordo, MD, FACC, FAHA, Senior Vice President, Clinical, Medical and Regulatory Affairs and Chief Medical Officer of Caladrius.

BASKING RIDGE, N.J. (April 9, 2018) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular indications, announces today that Douglas Losordo, M.D., FACC, FAHA, Senior Vice President of Clinical Medical and Regulatory Affairs and Chief Medical Officer, will participate at the following conferences in April: GTCbio 15th Stem Cell Summit Session: Advances in Adult Stem Cell Research Title: Recent Breakthroughs with…

Caladrius Biosciences Reports 2017 Fourth Quarter and Year End Financial Results Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J. (March 22, 2018) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular indications, announces financial results for the three and twelve months ended December 31, 2017 and provides a business update. Highlights of the 2017 fourth quarter and…

Conference call begins today at 4:30 p.m. Eastern Time  BASKING RIDGE, N.J. (March 15, 2018) – Caladrius Biosciences, Inc. (Nasdaq:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular indications, announces that the Company will release financial results for the three and twelve months ended December 31, 2017 after close of the U.S. financial markets on Thursday, March 22, 2018. Caladrius’ management will host a conference call…

BASKING RIDGE, N.J. (March 13, 2018) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular indications, announces today that the first patient has been dosed in the Company’s Phase 2 clinical trial in Japan with its proprietary CD34 cell therapy (CLBS12) for the treatment of no-option critical limb ischemia (“CLI”). This trial is a 35-patient prospective, randomized, controlled, multicenter study. Patients randomized…

BASKING RIDGE, N.J. (March 9, 2018) – Caladrius Biosciences, Inc. (Nasdaq:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular indications, today announces that management will be presenting at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium (CHIPS) taking place March 15-17, 2018 at the Intercontinental Hotel in Hangzhou, China. David J. Mazzo, PhD, President and Chief Executive Officer of Caladrius Biosciences, will present…

Treatment continues to be well-tolerated and deemed non-futile for therapeutic effect BASKING RIDGE, N.J. (March 8, 2018) – Caladrius Biosciences, Inc. (Nasdaq:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular indications, reports results from the predetermined interim analysis in The Sanford Project: T-Rex Study, a prospective, randomized, placebo-controlled, double-blind Phase 2 clinical trial of 110 patients to evaluate the safety and efficacy of the Company’s CLBS03…

License Expands Pipeline in Cardiovascular Disease based on Compelling Data Showing Improvement in Chest Pain, Exercise Capacity and Mortality BASKING RIDGE, N.J. (March 6, 2018) – Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology indications, announces today that the Company acquired from Shire plc (LSE: SHP, NASDAQ: SHPG) an exclusive worldwide license to data from a late stage CD34+ cell therapy program for…

BASKING RIDGE, N.J. (February 7, 2018) – Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology indications, today announces that management will be participating in the 2018 BIO CEO & Investor Conference taking place February 12-13, 2018 at the New York Marriott Marquis. David J. Mazzo, PhD, President and Chief Executive Officer of Caladrius Biosciences, will present a company overview on Monday, February 12,…

Caladrius Biosciences Announces Completion of Enrollment of Phase 2 T-Rex Clinical Trial of CLBS03 for Type 1 Diabetes Primary endpoint topline data to be reported in early 2019 BASKING RIDGE, N.J. (January 18, 2018) – Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology indications, announces the completion of enrollment in The Sanford Project: T-Rex Study, a prospective, randomized, placebo-controlled, double-blind Phase 2 clinical…

BASKING RIDGE, N.J. (December 1, 2017) – Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology indications, announces today that David J. Mazzo, PhD, President and Chief Executive Officer of the Company, will present at the 10th Annual LD Micro Main Event on Thursday, December 7, 2017 at 10:30 a.m. PST at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.

Conference call begins today at 4:30 p.m. Eastern Time BASKING RIDGE, N.J., (November 9, 2017) – Caladrius Biosciences, Inc. (NASDAQ: CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology indications, announces results for the three and nine months ended September 30, 2017. Highlights of the 2017 third quarter and recent weeks include: Enrolled the 70th subject in The Sanford Project: T-Rex Study (the “T-Rex Study”), a prospective,…

BASKING RIDGE, N.J. (November 2, 2017) – Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology indications, announces that the Company will release financial results for the three and nine months ended September 30, 2017 on Thursday, November 9, 2017.